Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 15, 31-37, January 1, 1955]
© 1955 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davidson, J. D.
Right arrow Articles by Freeman, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davidson, J. D.
Right arrow Articles by Freeman, B. B.

The Effects of Antitumor Drugs upon P32 Incorporation into Nucleic Acids of Mouse Tumors* ,{dagger}

Jack D. Davidson{ddagger} and Betty B. Freeman

( Francis Delafield Hospital and the Institute of Cancer Research, College of Physicians and Surgeons Columbia University, New York, N.Y.)

The influence of effective antitumor chemotherapeutic agents upon the rate of incorporation of P32 into the DNA of Adenocarcinoma 755 in mice was studied.

No influence upon this index of nucleic acid synthesis was observed in the case of the alklylating agents, Myleran, nitrogen mustard, triethylene melamine, or triethylene phosphoramides, despite dose levels adequate to inhibit tumor growth. The purine analogs, 8-azaguanine and 6-mercaptopurine, caused depression of nucleic acid synthesis. This contrast suggests the existence of fundamentally different mechanisms of action for the two classes of compounds with primary inhibition of nucleic acid synthesis applying only in the case of the purine antimetabolites.

* This investigation was supported in part by the Damon Runyon Fund and a research grant (C-2046) from the National Cancer Institute, National Institute of Health, Public Health Service, Department of Health, Education and Welfare.

{dagger} Presented in part before the 44th annual meeting of the American Association for Cancer Research, April, 1953, Chicago, Illinois, and published is abstract form in the Scientific Proceedings of that meeting.

{ddagger} Fellow in Cancer Research of the American Cancer Society.

Received 8/ 3/54.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1955 by the American Association for Cancer Research.